Purpose To assess the effect of diagnostic mydriasis with 1% cyclopentolate on the intraocular pressure (IOP) of patients attending glaucoma, medical retina and cataract clinics. Methods Levels of ...
To investigate whether pharmacological mydriasis influences interobserver agreement or within-observer agreement (comparing estimates made before and after dilation) in the evaluation of the optic ...
First-in-class fixed combination mydriatic agent demonstrated robust efficacy, good tolerability in confirmatory MIST-2 Study NEW YORK, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), ...
First-in-class fixed combination mydriatic agent demonstrated robust efficacy, high tolerability; Study further validates OpteJet™ platform delivery technology Company to host conference call at 8:30 ...
NEW YORK, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in connection with its ...
NEW YORK, May 08, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company developing the Optejet® device for use both in connection with its own drug-device ...
Mydriasis is the medical term for an unusual dilation or widening of the pupils. There are various causes of this fixed dilation of the pupils. Normally, a person’s pupils dilate when the light is dim ...
There are typically no visual changes in the initial stages of glaucoma. As damage occurs to the optic nerve, people may develop blind spots in their peripheral visual field. Some can see halos and ...
Viatris Inc., a global healthcare company, announced the US commercial launch of Ryzumvi (phentolamine ophthalmic solution) 0.75% for the treatment of pharmacologically-induced mydriasis produced by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results